Dr. Stanley Hazen’s long-term studies of HDL are profoundly altering our view of HDL and its role in heart disease — and may soon yield a diagnostic assay for cardiac risk based on the new insights.
There’s no arguing that rhBMP-2 forms bone. The latest research aims to learn whether its adverse effects outweigh its benefits, and in which types of spine fusion procedures the risk-benefit ratio is most favorable.
Amputation can often be avoided by taking a multidisciplinary, state-of-the-art approach to limb revascularization that includes addressing underlying risk factors.
Low-grade inflammation in celiac disease doubles the risk of coronary artery disease in patients of any age.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Study finds that not accounting for individual risk factors can lead to mistakes in prescribing anticoagulants, which can increase morbidity and mortality in cancer patients.
HIV patients who undergo cardiac surgery have no increased inpatient mortality risk, lower rates of stroke and similar rates of infection and complications as HIV-negative patients.
Even with an estimated 44 million people living with Alzheimer s disease (AD), relatively few new AD drugs are in development. Additionally, the failure rate for AD drug development is 99.6 percent from the years 2002 to 2012 and the number of AD drugs has been declining since 2009. In a new analysis published today, researchers say there is an urgent need to increase the number of agents entering the AD drug development pipeline.
Left-ventricular assist devices (LVADs) are a viable alternative to transplant for some patients, and today s smaller devices make these an option for more patients with heart failure
New patient safety and quality programs are limiting reimbursement to hospitals for substandard care and readmissions. Reducing the number and cost of complications can help maximize reimbursement.
Cleveland Clinic researchers have discovered the first example of a genetic alteration that increases the conversion of precursor steroids to 5α-dihydrotestosterone (DHT), permitting prostate tumors to grow in the absence of gonadal testosterone.